Pain VAS Scale 0‐10 · patients with chronic LBP
1 finding from 1 review
Arhus Index Scale 0‐130 Pain VAS Scale 0‐10 · patients with chronic LBP
1 finding from 1 review
Pruritus · patients with chronic kidney disease (CKD) pruritus
1 finding from 1 review
Quality of life ‐ not measured · patients with chronic kidney disease (CKD) pruritus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction ‐ not measured · patients with chronic kidney disease (CKD) pruritus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression ‐ not measured · patients with chronic kidney disease (CKD) pruritus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse drug reaction (ADR) per participant · patients with chronic kidney disease (CKD) pruritus
Summary of findings table ‐ Kappa‐opioid agonists may leads to higher risk for at least one adverse drug reaction (ADR) per patient compared with placebo (low certainty).
1 finding from 1 review
Progression of endometrial hyperplasia to endometrial cancer · endometrial hyerplasia
It is very uncertain whether summary of findings table ‐ Metformin + megestrol changes progression of endometrial hyperplasia to endometrial cancer compared with megestrol (very low certainty).
1 finding from 1 review
Hysterectomy rate · endometrial hyerplasia
It is very uncertain whether summary of findings table ‐ Metformin + megestrol changes hysterectomy rate compared with megestrol (very low certainty).
1 finding from 1 review
Abnormal uterine bleeding ‐ not measured · endometrial hyerplasia
The review found no eligible studies for this question.
1 finding from 1 review
HRQOL ‐ not measured · endometrial hyerplasia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects during treatment · endometrial hyerplasia
1 finding from 1 review
Regression of endometrial hyperplasia (with or without atypia) to proliferative, secretory, or atrophic endometrium · endometrial hyerplasia
Summary of findings table ‐ Metformin + megestrol may leads to higher regression of endometrial hyperplasia (with or without atypia) to… compared with megestrol (low certainty).
1 finding from 1 review
Recurrence of endometrial hyperplasia · endometrial hyerplasia
1 finding from 1 review
Annualized joint Bleeding Rate (AjBR) · people with inhibitors
1 finding from 1 review
QoL · people with inhibitors
1 finding from 1 review
Proportion with zero bleeds · people with inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher proportion with zero bleeds compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
All adverse events · people with inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · people with inhibitors
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people without inhibitors
1 finding from 1 review